SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

☒	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~December~~March 31, ~~2017~~2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 0-6658

SCIENTIFIC INDUSTRIES, INC.

Delaware	04-2217279
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

80 Orville Drive, Suite 102, Bohemia, New York	11716
(Address of principal executive offices)	(Zip Code)

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐(Do not check if a smaller reporting company)	Smaller reporting company ☒
	Emerging Growth ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act)

Yes☐ No ☒

SCIENTIFIC INDUSTRIES, INC.

PART I - Financial Information

Item 1.	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

	Condensed Consolidated Balance Sheets	12

	Condensed Consolidated Statements of Operations	23

	Condensed Consolidated Statements of ~~Comprehensive Income (Loss)~~Changes in Shareholders’ Equity	34

	Condensed Consolidated Statements of Cash Flows	45

	Notes to Unaudited Condensed Consolidated Financial Statements	5 6

Item 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	12 16

Item 4.	CONTROLS AND PROCEDURES	14 17

PART II - Other Information


Item 6.	EXHIBITS AND REPORTS ON FORM 8-K	14 18

~~SIGNATURE~~S IGNATURE		15 19

PART I – FINANCIAL INFORMATION

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

LIABILITIES AND SHAREHOLDERS’ EQUITY

Shareholders’ equity:

Common stock, $.05 par value; 10,000,000 and 7,000,000 shares authorized; 2,882,065 and 2,881,065 shares issued; 2,862,263 and 2,861,263 shares outstanding at March 31, 2021 and

June 30, 2020

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

For the Three Month Period Ended
December 31,

For the Three Month Period Ended
December 31,

For the Six Month Period Ended
December 31,

For the Six Month Period Ended
December 31,

2017

2016

2017

2016

Revenues
$1,892,400
$2,683,800
$3,173,300
$4,242,900





Cost of revenues
  1,126,700
  1,888,900
  1,955,900
  2,778,400





Gross profit
  765,700
  794,900
  1,217,400
  1,464,500





Operating expenses:




General and administrative
  407,900
  409,200
  836,300
  821,600
Selling
  214,600
  224,200
  415,600
  440,900
Research and development
  132,900
  105,000
  262,000
  220,400





Total operating expenses
  755,400
  738,400
  1,513,900
  1,482,900





Income (loss) from operations
  10,300
  56,500
  (296,500)
  (18,400)





Other income (expense):




Interest income
  5,200
  8,800
  5,600
  9,100
    Other income, net
  1,400
  400
  1,400
  5,700
    Interest expense
  (500)
  (900)
  (600)
  (1,100)





Total other income, net
  6,100
  8,300
  6,400
  13,700





Income (loss) before income tax expense (benefit)
  16,400
  64,800
  (290,100)
  (4,700)





Income tax expense (benefit):




Current
   71,800
  20,900
8,000
  (15,400)
Deferred
25,600
  (1,400)
  15,500
  14,100





Total income tax expense (benefit)
                    97,400
  19,500
23,500
  (1,300)





Net income (loss)
$(81,000)
$45,300
$(313,600)
$(3,400)





Basic earnings (loss) per common share
$(.05)
$.03
$(.21)
$.00





Diluted earnings (loss) per common share
$.(05)
$.03
$(.21)
$.00





Cash dividends declared per common share
$.00
$.03
$.00
$.03

	For the Three Month Period Ended March 31,	For the Three Month Period Ended March 31,	For the Nine Month Period Ended March 31,	For the Nine Month Period Ended March 31,
	2021	2020	2021	2020

Revenues	$2,508,600	$2,136,200	$7,245,100	$6,234,500

Cost of revenues	1,145,700	1,037,000	3,419,400	2,978,900

Gross profit	1,362,900	1,099,200	3,825,700	3,255,600

Operating expenses:
General and administrative	1,385,600	509,700	2,441,700	1,458,100
Selling	1,386,100	344,900	2,658,900	880,300
Research and development	450,000	298,900	1,024,000	795,300
Termination costs	-	180,700	-	180,700

Total operating expenses	3,221,700	1,334,200	6,124,600	3,314,400

Loss from operations	(1,858,800)	(235,000)	(2,298,900)	(58,800)

Other income (expense):
Other income (expense), net	6,100	(42,200)	22,300	(40,100)
Interest income	22,500	300	71,400	10,000
Total other income (expense), net	28,600	(41,900)	93,700	(30,100)

Loss before income tax (benefit)	(1,830,200)	(276,900)	(2,205,200)	(88,900)

Income tax (benefit), deferred:	(378,200)	(45,500)	(472,300)	(15,000)


Net loss from continuing operations	(1,452,000)	(231,400)	(1,732,900)	(73,900)

Discontinued operations (Note 9):

Income (loss) from discontinued operations (including loss on disposal of $405,400), in 2021 period	16,400	(99,600)	(758,400)	(360,300)
Income tax (benefit), deferred	-	(16,400)	(179,900)	(67,000)

Net income (loss) from discontinued operations	16,400	(83,200)	(578,500)	(293,300)

Net loss	$(1,435,600)	$(314,600)	$(2,311,400)	$(367,200)

Basic and diluted income (loss) per common share

Continuing operations	$(.51)	$(.15)	$(.61)	$(.05)

Discontinued operations	$.01	$(.06)	$(.20)	$(.20)
	��
Consolidated operations	$(.50)	$(.21)	$(.81)	$(.25)

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF ~~COMPREHENSIVE INCOME (LOSS)~~CHANGES IN SHAREHOLDERS' EQUITY (UNAUDITED)

For the Three Month Period Ended
December 31,

For the Three Month Period Ended
December 31,

For the Six Month Period Ended
December 31,

For the Six Month Period Ended
December 31,

2017

2016

2017

2016

Net income (loss)
$(81,000)
$45,300
$(313,600)
$(3,400)





Other comprehensive income (loss):




Unrealized holding gain (loss)




arising during period,




net of tax
  1,600
  (8,000)
  4,200
  (6,900)





Comprehensive Income (loss)
$(79,400)
$37,300
$(309,400)
$(10,300)

			Additional				Total
	Common Stock		Paid-in	Retained	Treasury Stock		Shareholders’
Fiscal Year 2021:	Shares	Amount	Capital	Earnings	Shares	Amount	Equity

Balance, July 1, 2020	2,881,065	$144,100	$8,608,300	$3,021,400	19,802	$52,400	$11,721,400

Net loss	-	-	-	(263,300)	-	-	(263,300)

Stock-based compensation	-	-	61,300	-	-	-	61,300

Balance, September 30, 2020	2,881,065	144,100	8,669,600	2,758,100	19,802	52,400	11,519,400

Net loss	-	-	-	(612,500)	-	-	(612,500)

Stock-based compensation	-	-	76,100	-	-	-	76,100

Balance, December 31, 2020	2,881,065	$144,100	$8,745,700	$2,145,600	19,802	$52,400	$10,983,000

Net loss	-	-	-	(1,435,600)	-	-	(1.435,600)

Stock-based compensation	-	-	1,292,000	-	-	-	1,292,000

Stock options exercised	1,000	100	2,900	-	-	-	3,000

Balance, March 31, 2021	2,882,065	$144,200	$10,040,600	$710,000	19,802	$52,400	$10,842,400

~~See notes to unaudited condensed consolidated financial statements.~~

			Additional				Total
	Common Stock		Paid-in	Retained	Treasury Stock		Shareholders’
Fiscal Year 2020:	Shares	Amount	Capital	Earnings	Shares	Amount	Equity

Balance, July 1, 2019	1,513,914	$75,700	$2,592,700	$3,724,700	19,802	$52,400	$6,340,700

Net loss	-	-	-	(56,200)	-	-	(56,200)

Stock options exercised	2,000	100	6,900	-	-	-	7,000

Stock-based compensation	-	-	17,700	-	-	-	17,700

Balance, September 30, 2019	1,515,914	75,800	2,617,300	3,668,500	19,802	52,400	6,309,200

Net income	-	-	-	3,600	-	-	3,600

Stock options exercised	6,661	300	(300)	-	-	-	-

Stock-based compensation	-	-	17,700	-	-	-	17,700

Balance, December 31, 2019	1,522,575	$76,100	$2,634,700	$3,672,100	19,802	$52,400	$6,330,500

Net loss	-	-	-	(314,600)	-	-	(314,600)

Stock-based compensation	-		14,600	-	-	-	14,600

Balance, March 31, 2020	1,522,575	$76,100	$2,649,300	$3,357,500	19,802	$52,400	$6,030,500

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	For the Six Month Period Ended December 31,	For the Six Month Period Ended December 31,
	2017	2016	For the Nine Month Period March 31,
			2021	2020
Operating activities:
Net loss	$(313,600)	$(3,400)	$(2,311,400)	$(367,200)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on sale of investment	-	(2,600)
Adjustments to reconcile net loss to cash used in operating activities:
Gain on sale of investments			(34,600)	(4,000)
Unrealized holding loss on investments			18,900	42,700
Depreciation and amortization	154,100	189,500	126,700	123,300
Deferred income taxes	16,500	14,100	(652,300)	(82,100)
Income tax benefit of stock options exercised	8,000	-
Loss on disposal of subsidiary			405,400	-
Stock-based compensation	12,400	1,000	1,429,400	50,000
Gain on sale of fixed assets			-	(300)
Change in fair value of contingent consideration			(118,500)	60,000
Changes in operating assets and liabilities:
Trade accounts receivable	(50,900)	(436,100)	(758,500)	(210,000)
Inventories	(431,400)	287,100	(697,700)	(452,500)
Prepaid expenses and other current assets	(66,300)	(75,300)
Right - of- use assets			87,700	(867,400)
Income tax receivable			(1,500)	-
Prepaid and other current assets			57,400	9,500
Lease liabilities			(51,000)	933,300
Accounts payable	240,200	(42,200)	142,600	(117,100)
Customer advances	321,800	17,000
Contract liabilities			(20,000)	116,100
Bank overdraft			7,500	-
Accrued expenses	(24,500)	(399,400)	(222,600)	(38,100)

Total adjustments	179,900	(446,900)	(281,100)	(436,600)

Net cash used in operating activities	(133,700)	(450,300)	(2,592,500)	(803,800)

Investing activities:
Redemption of investment securities, available-for-sale	-	11,100
Purchase of investment securities, available for sale	(15,000)	(18,700)
Redemption of investment securities			1,631,000	53,600
Purchase of investment securities			(6,609,200)	(62,800)
Proceeds from sale of discontinued operations			440,000	-
Proceeds from sale of fixed assets			-	1,000
Capital expenditures	(68,100)	(4,700)	(183,700)	(38,100)
Purchase of other intangible assets	(1,500)	(14,700)	(41,200)	(20,000)

Net cash used in investing activities	(84,600)	(27,000)	(4,763,100)	(66,300)

Financing activities:
Line of credit proceeds	40,000	250,000
Payments for contingent consideration	(142,700)	(117,400)
Principal payments on notes payable	(3,400)	(3,200)
Payments of contingent consideration			(13,400)	-
Proceeds from Payroll Protection Program			433.800	-
Proceeds from stock options exercised			3,000	7,000

Net cash provided by (used in) financing activities	(106,100)	129,400
Net cash provided by financing activities			423,400	7,000

Net decrease in cash and cash equivalents	(324,400)	(347,900)	(6,932,200)	(863,100)

Cash and cash equivalents, beginning of year	1,025,100	1,245,000	7,559,700	1,602,500

Cash and cash equivalents, end of period	$700,700	$897,100	$627,500	$739,400

Supplemental disclosures:

Cash paid during the period for:
Income taxes	$16,000	$186,000	$2,500	$40,900
Interest	600	1,100

See notes to unaudited condensed consolidated financial statements.

4 5

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

General:

The accompanying unaudited interim condensed consolidated financial statements are prepared pursuant to the Securities and Exchange Commission’s rules and regulations for reporting on Form 10-Q. Accordingly, certain information and footnotes required by accounting principles generally accepted in the United States for complete financial statements are not included herein. The Company believes all adjustments necessary for a fair presentation of these interim statements have been included and that they are of a normal and recurring nature. These interim statements should be read in conjunction with the Company’s financial statements and notes thereto, included in its Annual Report on Form 10-K, for the fiscal year ended June 30, ~~2017.~~2020. The results for the three ~~months~~ and ~~six~~nine months ended ~~December~~March 31, ~~2017,~~2021 are not necessarily an indication of the results for the full fiscal year ending June 30, ~~2018.~~2021.

1. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying ~~condensed~~ consolidated financial statements include the accounts of Scientific Industries, Inc., Scientific Bioprocessing, Inc. (“SBI”) a Delaware corporation and wholly-owned subsidiary, and Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary ~~Scientific Bioprocessing, Inc. (“SBI”)~~(discontinued as of November 2020), ~~a Delaware corporation and wholly-owned subsidiary,~~ and Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary (all collectively referred to as the “Company”). All material intercompany balances and transactions have been eliminated.

~~Recent~~COVID-19 Pandemic

The challenges posed by the COVID-19 pandemic on the global economy began to impact the Company’s operations at the end of the third quarter of the year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action as it pertains to COVID-19 preparedness by implementing the Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self -quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. However, if an employee becomes infected in the future, and the Company is forced to shut down for a period of time, it could have a short-term negative impact on operations. At the beginning of the pandemic, the Catalyst Research Instruments (“discontinued operation”) and Bioprocessing Systems Operations were shut down due to state mandates, however, the impact on operations was immaterial, and the Company was able to retain its employees without furloughs or layoffs, in part, due to the Company’s receipt of certain loan amounts under the Federal Government’s Paycheck Protection Program. The Company did not experience and does not anticipate any material impact on its ability to collect its accounts receivable due to the nature of its customers, which are primarily distributors of laboratory equipment and supplies that have the ability to pay. However, there were some delays in receiving some accounts receivable due for the discontinued operation due to customer shutdowns, and there was a material negative impact on the revenues of the discontinued operation. The Company has not experienced and does not anticipate any material impairment to its tangible and intangible assets, system of internal controls, supply chain, or delivery and distribution of its products as a result of COVID-19, however the ultimate impact of COVID-19 on the Company’s business, results of operations, financial condition and cash flows is dependent on future developments, including the duration or worsening of the pandemic and the related length of its impact on the global economy, which are uncertain and cannot be predicted at this time.

Adopted Accounting Pronouncements

In ~~January 2016,~~August 2018, the Financial ~~Accounting~~ Standards Board (“FASB”) issued ~~ASU No. 2016-01, “Financial Instruments - Overall (Subtopic 825-10)~~Accounting Standards Update ("ASU") 2018-13, "Fair Value Measurement (Topic 820): ~~Recognition and Measurement~~Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement", which is part of ~~Financial Assets and Financial Liabilities”.~~the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The ~~update addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. For public business entities, the~~ amendments in ~~this update are~~the new guidance remove, modify, and add certain disclosure requirements related to fair value measurements covered in Topic 820, "Fair Value Measurement." The new standard was effective for fiscal years beginning after December 15, ~~2017, including interim periods within those fiscal years.~~2019. Early adoption iswas permitted for either the entire standard oronly ~~for~~the requirements that modify or eliminate the disclosure requirements, with certain ~~portions of the ASU related~~requirements applied prospectively, and all other requirements applied retrospectively to ~~financial liabilities. The Company is currently evaluating the impact of the provisions of this new standard on the consolidated financial statements.~~

In February 2016, the FASB issued ASU No. 2016-02, “Leases” (Topic 842). The FASB issued this update to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The updated guidance is effective for annualall periods ~~beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company is currently evaluating the effect of the new standard.~~

~~In April 2016, the FASB issued ASU No. 2016-10,~~ ~~“Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing (Topic 606)”.~~ In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross verses Net) (Topic 606)”. These amendments provide additional clarification and implementation guidance on the previously issued ASU 2014-09, “Revenue from Contracts with Customers”. The amendments in ASU 2016-10 provide clarifying guidance on materiality of performance obligations; evaluating distinct performance obligations; treatment of shipping and handling costs; and determining whether an entity’s promise to grant a license provides a customer with either a right to use an entity’s intellectual property or a right to access an entity’s intellectual property. The amendments in ASU 2016-08 clarify how an entity should identify the specified good or service for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements.presented. The adoption of ~~ASU 2016-10 and ASU 2016-08 is to coincide with an entity’s adoption of ASU 2014-09.~~ The Company has performed a review of the requirements of the new guidance and has identified which of its revenue streams will be within the scope of ASC 606. The Company has applied the five-step model of the newthis standard ~~to a selection of contracts within each of its revenue streams and has compared the results to its current accounting practices. Based~~ on ~~this analysis, the Company does~~July 1, 2020 did not ~~currently expect~~have a material impact on the Company’s ~~consolidated~~ financial statements. The Company is expecting to utilize the modified retrospective transition method of adoption. The Company is continuing to work through the remaining steps of the adoption plan to facilitate adoption effective July 1, 2018. As part of this, the Company is assessing changes that might be necessary to information technology systems, processes, and internal controls to capture new data and address changes in financial reporting. The Company will be revising its revenue recognition accounting policy and expanding revenue disclosures to reflect the requirements of ASC 606, which include disclosures related to the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgements and assets recognized from the costs to obtain or fulfill a contract.

Recent Accounting Pronouncements

In ~~May 2016,~~December 2019, the FASB issued ASU No. ~~2016-12,~~ ~~“Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients”,~~2019-12, Simplifying the Accounting for Income Taxes, which ~~narrowly amended~~is designed to simplify the ~~revenue recognition guidance regarding collectibility, noncash consideration, presentation of sales tax and transition and is effective during~~accounting for income taxes by removing certain exceptions to the ~~same period as~~general principles in Topic 740. ASU ~~2014-09.The Company is currently evaluating the effect of the standard.~~

~~In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments”. This update provides guidance on how to record eight specific cash flow issues. This update~~No. 2019-12 is effective for fiscal years beginning after December 15, ~~2017, and~~2020, including interim periods within those fiscal ~~years. Early adoption is permitted and a retrospective transition method to each period should be presented. The Company is currently evaluating the effect of~~years; this ~~update on its consolidated financial statements.~~

~~In November 2016, the FASB issued~~ ASU ~~2016-18,~~ ~~“Statement of Cash Flows (Topic 230)”~~, requiring that the statement of cash flows explain the change in the total cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. This guidance is effectiveallows for ~~fiscal years, and interim reporting periods therein, beginning after December 15, 2017 with~~ early adoption ~~permitted. The provisions of this guidance are to be applied using a retrospective approach which requires application~~in any interim period after issuance of the ~~guidance for all periods presented.~~update. The Company is currently evaluating the impact of adopting this guidance.

2. Revenue

The Company records revenues in accordance with Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers, as amended” (“ASC Topic 606”). In accordance with ASC Topic 606, the ~~new standard~~Company accounts for a customer contract when both parties have approved the contract and ~~does not expect~~are committed to perform their respective obligations, each party’s rights can be identified, payment terms can be identified, the ~~adoption~~contract has commercial substance, and it is probable that the Company will ~~have a material effect on its consolidated financial statements and disclosures.~~collect substantially all of the consideration to

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

which it is entitled. Revenue is recognized when, or as, performance obligations are satisfied by transferring control of a promised product or service to a customer.

Nature of Products and Services

We generate revenues from the following sources: (1) Benchtop Laboratory Equipment, and (2) Bioprocessing Systems.

The following table summarizes the Company’s disaggregation of revenues for the three and nine months ended March 31, 2021 and 2020.

	Benchtop Laboratory Equipment	Bioprocessing Systems	Consolidated
Three Months Ended March 31, 2021:

Revenues	$2,365,700	$142,900	$2,508,600

Foreign Sales	942,200	102,600	1,044,800

	Benchtop Laboratory Equipment	Bioprocessing Systems	Consolidated
Three Months Ended March 31, 2020:

Revenues	$1,800,700	$335,500	$2,136,200

Foreign Sales	743,000	335,000	1,078,000

	Benchtop Laboratory Equipment	Bioprocessing Systems	Consolidated
Nine Months Ended March 31, 2021:

Revenues	$6,803,300	$441,800	$7,245,100

Foreign Sales	2,724,800	395,000	3,119,800

	Benchtop Laboratory Equipment	Bioprocessing Systems	Consolidated
Nine Months Ended March 31, 2020:

Revenues	$5,320,300	$914,200	$6,234,500

Foreign Sales	1,996,400	913,700	2,910,100

Benchtop Laboratory Equipment sales are comprised primarily of standard benchtop laboratory equipment from its stock sold to laboratory equipment distributors, or to end users primarily via e-commerce. The sales cycle from time of receipt of order to shipment varies from one day to up to a few weeks. Customers pay either by credit card (online sales) or net 30-90, depending on the customer. Once the item is shipped under the terms specified in the order, which is typically “FOB Factory”, other than a standard warranty, there are no obligations to the customer. The Company’s standard warranty is typically comprised of one to two years of parts and labor and is deemed immaterial.

Bioprocessing Systems’ revenues are primarily comprised of royalties earned by the Company, which are paid on a calendar year basis, under a licensing agreement from a single licensee and its sublicensees. The Company is obligated to pay 50% of all royalties it receives to the entity that licenses the intellectual property to the Company. During the year, the Company’s management uses its best judgement to estimate the royalty revenues earned during each fiscal period.

~~Adopted Accounting Pronoucements~~

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

~~In November 2015, the FASB issued ASU No. 2015-17, "Income Taxes: Balance Sheet Classification of Derffered Taxes~~" (ASU 2015-17") which was effective for fiscal years begining December 15, 2016 (fiscal 2018 for the Company). ASU 2015-17 required that deferred tax assets and liabilities be net and classified as noncurrent on the balance sheet rather than presenting deferred taxes into current and noncurrent amounts. The Company adopted ASU 2015-07 effective for the first fiscal quarter of the year ending June 30, 2018. The Company applied the new guidance on a respective basis, resulting in a reclassification of current deferred tax assets totaling $129,000 against long term deferred tax assets in the Company's Condensed Consolidated Balance Sheet as of June 30, 2017. The adoption of this ASU had no impact on the Company’s Condensed Consolidated Statement of Operations.

~~On December 22, 2017, the Staff of the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118, “Income Tax Accounting Implications of the Tax Cuts and Jobs Act, or~~ ~~SAB 118,~~” ~~which addresses situations where the accounting under the FASB, Accounting Standards Codification No. 740,~~ ~~Income Taxes,~~ or ASC 740 is incomplete for certain income tax effects of Public Law No. 115-97, commonly referred to as the Tax Cuts and Jobs Act, or the 2017 Tax Act, by the time an entity issues its financial statements for the fiscal period that includes the date the 2017 Tax Act was enacted.

Under ASC 740, entities are required to adjust current and deferred tax assets and liabilities for the effects of changes in tax laws or rates at their date of enactment. However, pursuant to SAB 118, if an entity does not have the necessary information available, prepared, or analyzed for certain income tax effects of the 2017 Tax Act at the time an entity’s financial statements are issued, an entity shall apply ASC 740 based on the provisions of the tax laws that were in effect immediately prior to the enactment of the 2017 Tax Act. If the accounting for certain income tax effects of the 2017 Tax Act is incomplete, but an entity can determine a reasonable estimate for those effects, an entity can record provisional amounts during a measurement period, which ends on the earlier of when an entity has obtained, prepared, and analyzed the information necessary to complete the accounting requirements of ASC 740 and December 22, 2017.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The ~~2017 Tax Act includes significant changes~~Company determines revenue recognition through the following steps:

	●	Identification of the contract, or contracts, with a customer
	●	Identification of the performance obligations in the contract
	●	Determination of the transaction price
	●	Allocation of the transaction price to the performance obligations in the contract
	●	Recognition of revenue when, or as, a performance obligation is satisfied

The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC Topic 606: 1) all revenues are recorded net of returns, allowances, customer discounts, and incentives; 2) although sales and other taxes are immaterial, the Company accounts for amounts collected from customers for sales and other taxes, if any, net of related amounts remitted to tax authorities; 3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; 4) the Company accounts for shipping and handling activities that occur after control transfers to the ~~U.S. income tax system. The 2017 Tax Act contains numerous provisions impacting~~customer as a fulfillment cost rather than an additional promised service and these fulfillment costs fall within selling expenses; 5) the Company is always considered the ~~most significant of which reduces~~principal and never an agent, because it has full control and responsibility until title is transferred to the ~~Federal corporate statutory rate from 35% to 21%. The~~customer; 6) the Company ~~is a fiscal-year end taxpayer and is required to use a blended statutory federal tax rate, inclusive~~does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the ~~Federal rate change enacted on December 22, 2017 to compute its effective rate for~~contract with the ~~three and six months ended December 31, 2017. The various provisions under~~customer such as is the 2017 Tax Act most relevant to the Company have been considered in the preparation of the financial statements as of December 31, 2017. However, as of December 31, 2017, the Company had not completed its accounting for the tax effects of the enactment of 2017 Tax act. The Company’s provision for income taxes for the three and six months ended December 31, 2017 is based on reasonable estimates of the effects of its implementation and existing deferred tax balances. The Company estimates it will record a one-time non-cash charge of approximately $30,000 for the fiscal year ended June 30, 2018 due to an estimated reduction in deferred tax assets as a result of the reduction in the Federal tax rate. We expect to complete our accounting during the one year measurement period from the enactment date.case with catalyst instruments.

2.3. Segment Information and Concentrations

The Company views its operations as ~~three~~two segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”), the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical and petrochemical companies sold on a direct basis (“Catalyst Research Instruments Operations”) and the design and marketing of bioprocessing systems and products and related royalty income (“Bioprocessing ~~Systems”~~Systems Operations”).

Segment information is reported as follows:

	Benchtop Laboratory Equipment	Bioprocessing Systems	Corporate And Other	Consolidated
Three Months Ended March 31, 2021:

Revenues	$2,365,700	$142,900	$-	$2,508,600

Foreign Sales	942,200	102,600	-	1,044,800

Income (Loss) From Operations	774,600	(1,722,200)	(911,200)	(1,858,800)

Assets	5,979,400	1,281,200	6,639,700	13,900,300

Long-Lived Asset Expenditures	18,600	92,100	-	110,700

Depreciation and Amortization	30,000	16,700	-	43,700

Benchtop Laboratory
Equipment

Catalyst Research
Instruments

Bioprocessing
Systems

Corporate
And Other

Consolidated

Three Months Ended December 31, 2017:

Revenues
$1,686,200
$153,500
$52,700
$-
$1,892,400






Foreign Sales
  815,300
  2,600
  -
  -
  817,900






    Income (Loss) From
    Operations
  122,000
  (103,400)
  (8,300)
  -
  10,300






Assets
  4,085,800
  1,613,200
  467,900
  803,300
6,970,200






    Long-Lived Asset
    Expenditures
  33,000
  1,900
  2,500
  -
  37,400






    Depreciation and
    Amortization
  67,000
  700
  9,300
  -
  77,000

Approximately $124,600 included in Assets relates to discontinued operations.

	Benchtop Laboratory Equipment	Bioprocessing Systems	Corporate And Other	Consolidated
Three Months Ended March 31, 2020:

Revenues	$1,800,700	$335,500	$-	$2,136,200

Foreign Sales	743,000	335,000	-	1,078,000

Income (Loss) From Operations	138,800	(193,100)	(180,700)	(235,000)

Assets	5,229,700	1,647,800	2,042,400	8,919,900

Long-Lived Asset Expenditures	4,900	11,700	-	16,600

Depreciation and Amortization	29,600	11,000	300	40,900

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Benchtop Laboratory
Equipment

Catalyst Research Instruments

Bioprocessing
Systems

Corporate
And Other

Consolidated

Three Months Ended December 31, 2016:

Revenues
$1,466,800
$1,192,100
$24,900
$-
$2,683,800






Foreign Sales
  751,800
  10,300
  -
  -
  762,100






    Income (Loss) From
    Operations
  62,600
  26,600
  (32,700)
  -
  56,500






Assets
  4,131,400
  1,982,800
  434,700
  695,900
7,244,800






    Long-Lived Asset
    Expenditures
  5,200
  -
  5,800
  -
  11,000






    Depreciation and
    Amortization
  76,700
  4,500
  12,600
  -
  93,800
Approximately $1,227,900 included in Assets relates to discontinued operations, and $300 in depreciation and amortization relates to discontinued operations.

Approximately ~~31%~~55% and ~~55%~~49% of ~~net~~total benchtop laboratory equipment sales ~~(48%~~(52% and ~~30%~~37% of total revenues) for the three ~~month periods~~months ended ~~December~~March 31, ~~2017~~2021 and ~~2016,~~2020, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately ~~12%~~20% and ~~21%~~24% of total benchtop laboratory equipment sales (19% and ~~11%~~18% of total revenues) were derived from the Torbal Scales Division for the three months ended ~~December~~March 31, ~~2017~~2021 and ~~2016,~~2020, respectively.

For the three months ended ~~December~~March 31, ~~2017~~2021 and ~~2016,~~2020, respectively, ~~two~~three customers accounted ~~in the aggregate~~ for approximately ~~10%~~26% and ~~17%~~16% of net sales of the Benchtop Laboratory Equipment Operations ~~(15%~~(25% and 9%12% of the Company’s total revenues). Sales of catalyst research instruments generally comprise a few very large orders averaging approximately $50,000 per order to a limited number of customers, who differ from order to order. Sales to one and three customers during the three months ended December 31, 2017 and 2016, accounted for approximately 74% and 99% of the Catalyst Research Instrument Operations’ revenues and 7% and 44% of the Company’s total revenues, respectively.

Benchtop Laboratory Equipment

Catalyst Research Instruments

Bioprocessing
Systems

Corporate
And Other

Consolidated

Six Months Ended December 31, 2017:

Revenues
$2,885,600
$182,300
$105,400
$-
$3,173,300






Foreign Sales
  1,317,600
  9,000
  -
  -
  1,326,600






    Income (Loss) From
    Operations
  28,100
  (287,500)
  (37,100)
  -
  (296,500)






Assets
  4,085,800
  1,613,200
  467,900
  803,300
6,970,200






    Long-Lived Asset
    Expenditures
  65,200
  1,900
  2,500
  -
  69,600






    Depreciation and
    Amortization
  131,900
  3,500
  18,700
  -
  154,100

Benchtop Laboratory Equipment

Catalyst Research Instruments

Bioprocessing
Systems

Corporate
And Other

Consolidated

Six Months Ended December 31, 2016:

Revenues
$2,923,600
$1,269,600
$49,700
$-
$4,242,900






Foreign Sales
  1,313,000
  15,100
  -
  -
  1,328,100






    Income (Loss) From
    Operations
  164,000
  (115,000)
  (67,400)
  -
  (18,400)






Assets
  4,131,400
  1,982,800
  434,700
  695,900
  7,244,800






    Long-Lived Asset
    Expenditures
  13,600
  -
  5,800
  -
  19,400






    Depreciation and
    Amortization
  153,400
  11,100
  25,000
  -
  189,500

	Benchtop Laboratory Equipment	Bioprocessing Systems	Corporate And Other	Consolidated
Nine Months Ended March 31, 2021:

Revenues	$6,803,300	$441,800	$-	$7,245,100

Foreign Sales	2,724,800	395,000	-	3,119,800

Income (Loss) From Operations	1,727,000	(2,996,300)	(1,029,600)	(2,298,900)

Assets	5,979,400	1,281,200	6,639,700	13,900,300

Long-Lived Asset Expenditures	54,100	170,800	-	224,900

Depreciation and Amortization	79,700	46,500	500	126,700

Approximately ~~36%~~$124,600 included in Assets relates to discontinued operations, and ~~52%~~$500 in depreciation and amortization relates to discontinued operations.

	Benchtop Laboratory Equipment	Bioprocessing Systems	Corporate And Other	Consolidated
Nine Months Ended March 31, 2020:

Revenues	$5,320,300	$914,200	$-	$6,234,500

Foreign Sales	1,996,400	913,700	-	2,910,100

Income (Loss) From Operations	331,300	(209,400)	(180,700)	(58,800)

Assets	5,229,700	1,647,800	2,042,400	8,919,900

Long-Lived Asset Expenditures	26,800	31,300	-	58,100

Depreciation and Amortization	90,900	31,500	900	123,300

Approximately $1,227,900 included in Assets relates to discontinued operations, and $900 in depreciation and amortization relates to discontinued operations.

Approximately 51% and 45% of ~~net~~total benchtop laboratory equipment sales ~~(46%~~(47% and 36% of total revenues) for the ~~six month periods~~nine months ended ~~December~~March 31, ~~2017~~2021 and ~~2016,~~2020, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately ~~16%~~23% and ~~23%~~27% of total benchtop laboratory equipment sales (21% and ~~16%~~21% of total revenues) were derived from the Torbal Scales Division for the ~~six~~nine months ended ~~December~~March 31, ~~2017~~2021 and ~~2016,~~2020, respectively.

For the ~~six~~nine months ended ~~December~~March 31, ~~2017~~2021 and ~~2016, respectively, two~~2020, three customers accounted ~~in the aggregate~~ for approximately ~~11%~~23% and ~~16%~~17% of net sales of the Benchtop Laboratory Equipment Operations ~~(15%~~(21% and ~~11%~~13% of the Company’s total revenues).

Sales of catalyst research instruments generally comprise a few very large orders averaging approximately $50,000 per order to a limited number of customers, who differ from order to order. Sales to one and six customers during the six months ended December 31, 2017 and 2016, accounted for approximately 64% and 97% of the Catalyst Research Instrument Operations’ revenues and 4% and 29% of the Company’s total revenues,, respectively.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

3.4. Fair Value of Financial Instruments

The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements do not include transaction costs.

The accounting guidance also expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are described below:

Level 1 - Inputs that are based upon unadjusted quoted prices for identical instruments traded in active markets.

Level 2 - Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are observable, either directly or indirectly.

Level 3 - Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.

In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments. These calculations take into consideration the credit risk of both the Company and its counterparties. The Company has not changed its valuation techniques in measuring the fair value of any financial assets and liabilities during the period.

The fair ~~value~~values of the contingent consideration obligations are based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria. The measurement is based on significant inputs that are not observable in the market, therefore, the Company classifies this liability as Level 3 in the following tables.

The following tables set forth by level within the fair value hierarchy the Company’s financial assets that were accounted for at fair value on a recurring basis at ~~December~~March 31, ~~2017~~2021 and June 30, ~~2017~~2020 according to the valuation techniques the Company used to determine their fair values:

		Fair Value Measurements Using Inputs Considered as
	Fair Value at December 31, 2017	Level 1	Level 2	Level 3		Fair Value Measurements Using Inputs Considered as
					Fair Value at March 31, 2021	Level 1	Level 2	Level 3
Assets:

Cash and cash equivalents	$700,700		$-		$627,500		$-
Available for sale securities	314,700		-
Investment securities					5,325,700		-

Total	$1,015,400		$-		$5,953,200		-	$-

Liabilities:

Contingent consideration	$154,300	$-		$154,300	$226,100	$-		$226,100

		Fair Value Measurements Using Inputs Considered as
	Fair Value at June 30, 2020	Level 1	Level 2	Level 3
Assets:
Cash and cash equivalents	$7,559,700	$7,559,700	$-	$-
Investment securities	331,800	331,800	-	-

Total	$7,891,500	$7,891,500	$-	$-

Liabilities:

Contingent consideration	$358,000	$-	$-	$358,000

Fair Value Measurements Using Inputs Considered as

Fair Value at June 30, 2017

Level 1

Level 2

Level 3

Assets:

Cash and cash equivalents
$1,025,100
$1,025,100
$-
$-
Available for sale securities
  295,500
  295,500
  -
  -





Total
$1,320,600
$1,320,600
$-
$-





Liabilities:









Contingent consideration
$297,000
$-
$-
$297,000

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~The following table sets forth an analysis of changes during the six months ended December 31, 2017 and 2016 in Level 3 financial liabilities of the Company:~~

2017

2016

Beginning balance
$297,000
$346,300
Payments
  (142,700)
  (117,400)



Ending balance
$154,300
$228,900

Investments in marketable securities ~~classified as available-for-sale by security type~~ at ~~December~~March 31, ~~2017~~2021 and June 30, ~~2017~~2020 consisted of the following:

Cost

Fair Value

Unrealized Holding Gain (Loss)

At December 31, 2017:

Available for sale:

Equity securities
$46,300
$66,800
$20,500
Mutual funds
  267,700
  247,900
  (19,800)





$314,000
$314,700
$700

	Cost	Fair Value	Unrealized Holding Gain (Loss)
At March 31, 2021:
Equity securities	$102,200	$148,100	$45,900
Mutual and bond funds	5,169,700	5,177,600	7,900

	$5,271,900	$5,325,700	$53,800

Cost

Fair Value

Unrealized Holding Gain (Loss)

At June 30, 2017:

Available for sale:

Equity securities
$37,000
$50,800
$13,800
Mutual funds
  262,000
  244,700
  (17,300)





$299,000
$295,500
$(3,500)

	Cost	Fair Value	Unrealized Holding Gain (Loss)
At June 30, 2020:
Equity securities	$77,600	$101,900	$24,300
Mutual and bond funds	250,300	229,900	(20,400)

	$327,900	$331,800	$3,900

Inventories are valued at the lower of cost (determined on a first-in, first-out basis) or net realizable value, and have been reduced by an allowance for excess and obsolete inventories. The estimate is based on managements review of inventories on hand compared to estimated future usage and sales. Cost of work-in-process and finished goods inventories include material, labor, and manufacturing overhead.

56.. Goodwill and Other Intangible Assets

Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the Company’s acquisitions. Goodwill amounted to ~~$705,300~~$257,300 at ~~December~~March 31, ~~2017~~2021 and June 30, ~~2017,~~2020, all of which is expected to be deductible for tax purposes.

The components of other intangible assets are as follows:

Accumulated Amortization

Useful
Lives

Cost

Accumulated Amortization

Net

At June 30, 2017:

Technology, trademarks 5/10 yrs.
$662,800
$541,100
$121,700
Trade names 6 yrs.
  140,000
  77,800
  62,200
Websites 5 yrs.
  210,000
  140,000
  70,000
Customer relationships 9/10 yrs.
  357,000
  281,400
  75,600
Sublicense agreements 10 yrs.
  294,000
  165,400
  128,600
Non-compete agreements 5 yrs.
  384,000
  294,000
  90,000
IPR&D 3 yrs.
  110,000
  110,000
  -
Other intangible assets 5 yrs.
  194,500
  163,600
  30,900





$2,352,300
$1,773,300
$579,000
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

	Useful Lives	Cost	Accumulated Amortization	Net
At June 30, 2020:
Technology, trademarks	5/10 yrs.	$364,700	$362,000	$2,700
Trade names	6 yrs.	140,000	140,000	-
Websites	5 yrs.	210,000	210,000	-
Customer relationships	9/10 yrs.	120,000	84,400	35,600
Sublicense agreements	10 yrs.	294,000	253,600	40,400
Non-compete agreements	5 yrs.	282,000	282,000	-
IPR&D	3 yrs.	110,000	110,000	-
Other intangible assets	5 yrs.	246,600	196,600	50,000

		$1,767,300	$1,638,600	$128,700

Total amortization expense was ~~$61,100~~$16,000 and ~~$76,200~~$18,300 for the three months ended ~~December~~March 31, ~~2017~~2021 and ~~2016,~~2020, respectively, and ~~$122,200~~$48,500 and ~~$154,100~~$57,600 for the ~~six~~nine months ended ~~December~~March 31, ~~2017~~2021 and ~~2016,~~2020, respectively. As of ~~December~~March 31, ~~2017,~~2021, estimated future amortization expense related to intangible assets is ~~$124,700~~$42,800 for the remainder of the fiscal year ending June 30, ~~2018, $185,800 for fiscal 2019, $65,400 for fiscal 2020, $48,000 for fiscal~~ 2021, ~~$27,000~~$32,100 for fiscal 2022, $20,400 for fiscal 2023, $18,000 for fiscal 2024 and ~~$7,400~~$8,200 thereafter.

67.. Earnings (Loss) Per Common Share

~~Earnings (loss)~~The Company presents the computation of earnings per share (“EPS”) on a basic and diluted basis. Basic EPS is computed by dividing net income or loss by the weighted average number of shares outstanding during the reported period. Diluted EPS is computed similarly to basic EPS, except that the denominator is increased to include the number of additional common ~~share data was computed as follows:~~shares that would have been outstanding if the potential additional common shares that were dilutive had been issued. Common shares are excluded from the calculation if they are determined to be anti-dilutive. The following table sets forth the weighted average number of common shares outstanding for each period presented

For the Three Month Period Ended December 31, 2017

For the Three Month Period Ended December 31, 2016

For the Six Month Period Ended December 31, 2017

For the Six Month Period Ended December 31, 2016

   Net income (loss)
$(81,000)
$45,300
$(313,600)
$(3,400)





   Weighted average common shares outstanding
  1,494,112
  1,489,112
  1,494,112
  1,489,112





Basic and diluted earnings (loss) per common share
$(.05)
$.03
$(.21)
$(.00)

	For the Three Month Period Ended March 31, 2021	For the Three Month Period Ended March 31, 2020	For the Nine Month Period Ended March 31, 2021	For the Nine Month Period Ended March 31, 2020

Weighted average number of common shares outstanding	2,861,607	1,502,773	2,861,376	1,497,567
Effect of dilutive securities	-	-	-	-
Weighted average number of dilutive common shares outstanding	2,861,607	1,502,773	2,861,376	1,497,567

Basic and diluted earnings (loss) per common share

Continuing operations	$(.51)	$(.15)	$(.61)	$(.05)
Discontinued operations	$.01	$(.06)	$(.20)	$(.20)
Consolidated operations	$(.50)	$(.21)	$(.81)	$(.25)

Approximately ~~82,000~~259,357 shares and ~~43,500 shares~~1,349,850 of the ~~Company's~~Company’s common stock issuable upon the exercise of options and warrants, respectively, were excluded from the calculation for the three and nine months ended March 31, 2021, because the effect would be anti-dilutive due to the loss for the periods. Approximately, 51,629 shares of the Company’s common stock issuable upon the exercise of the outstanding options were excluded from the calculation ~~of diluted earnings per common share~~ for ~~the~~ three and ~~six month periods~~nine months ended ~~December~~March 31, ~~2017 and 2016, respectively,~~2020 because ~~the effect would be~~they were anti-dilutive.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The Company recognizes all long-term leases on its balance sheet as a liability for its lease obligation, measured at the present value of lease payments not yet paid, and a corresponding asset representing its right to use the underlying asset over the lease term.

The Company determines whether an agreement contains a lease at inception based on the Company’s right to obtain substantially all of the economic benefits from the use of the identified asset and its right to direct the use of the identified asset. Lease liabilities represent the present value of future lease payments and the Right-Of-Use (“ROU”) assets represent the Company’s right to use the underlying assets for the respective lease terms. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The ROU asset is further adjusted to account for previously recorded lease expenses such as deferred rent and other lease liabilities. As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate of 5.0% as the discount rate to calculate the present value of future lease payments, which was the interest rate that its bank would charge for a similar loan.

The Company elected not to recognize a ROU asset and a lease liability for leases with an initial term of twelve months or less. In addition to minimum lease payments, certain leases require payment of a proportionate share of real estate taxes and certain building operating expenses or payments based on an excess of a specified base. These variable lease costs are not included in the measurement of the ROU asset or lease liability due to unpredictability of the payment amount and are recorded as lease expenses in the period incurred. The Company’s lease agreements do not contain residual value guarantees.

Fiscal year ending June 30,	Amount
Remainder of 2021	$64,000
2022	260,300
2023	245,300
2024	195,900
2025	91,600
Total future minimum payments	$857,100
Less: Imputed interest	71,500

Total Present Value of Operating Lease Liabilities	$785,600

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

9. Discontinued Operations

Effective November 30, 2020, the Company, as part of its strategic shift to becoming a life sciences tool provider, sold its Catalyst Research Instruments Operations reporting segment through the sale by Altamira of substantially all of its assets, which comprised of fixed assets, and inventory to Beijing JWGB Sci. & Tech. Co. Ltd., a corporation formed under the laws of the People’s Republic of China (“JWGB”) for $440,000 payable in cash through January 2021, resulting in a $405,400 pre-tax loss. In order to preserve business continuity for the buyer, Altamira agreed to purchase certain components on behalf of JWGB for which JWGB agreed to reimburse Altamira. At March 31, 2021, JWGB paid the full $440,000 purchase price and $28,500 for component purchases made on its behalf. The Company retained all its receivables and payables related to sales made prior to November 30, 2020, certain inventory related to two work-in-process orders which will be shipped by the end of the fiscal year ending June 30, 2021, product warranty and other miscellaneous liabilities related to certain employee benefits, and expenses related to the closure of the Altamira facility, which was substantially completed at the end of December 2020.

As a result of the disposal described above, the operating results of the former Catalyst Research Instruments Operations segment have been presented as discontinued operations in the balance sheets, the statements of operations, and the statements of cash flows, as detailed below.

Assets:	March 31, 2021	June 30, 2020
Cash	$12,100	-
Accounts receivable	109,300	-
Inventories	3,200	$343,700
Property and equipment, net	-	1,400
Goodwill	-	447,900

Discontinued operations	$124,600	$793,000

Liabilities:	March 31, 2021	June 30, 2020
Accounts payable	$2,900	$20,100
Accrued expenses and taxes	45,000	120,700
Contract liabilities	16,500	69,000
Operating lease liabilities, current portion	-	31,100

	$64,400	$240,900

	Three Months Ended		Nine Months Ended
	March 31, 2021	March 31, 2020	March 31, 2021	March 31, 2020
Revenues	$107,800	$241,800	$387,700	$420,000
Cost of goods sold	78,800	237,700	458,500	500,300
Gross profit	29,900	4,100	(70,800)	(80,300)
Selling, general and administrative expenses	12,600	103,700	282,200	280,000
Income (loss from operations)	16,400	(99,600)	(353,000)	(360,300)
Loss on disposal	-	-	(405,400)	-
Income (loss) before income tax benefit	16,400	(99,600)	(758,400)	(360,300)
Income tax benefit, all deferred	-	(16,400)	(179,900)	(67,000)
Net income (loss) attributable to discontinued operations	$16,400	$(83,200)	$(578,500)	$(293,300)

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

In our Consolidated Statements of Cash Flows, the cash flows from discontinued operations are not separately classified. Cash (used) and provided by operating activities from discontinued operations for the nine months ended March 31, 2021 and March 31, 2020 was ($502,900) and $17,900, respectively. Cash provided by investing activities from discontinued operations for the nine months ended March 31, 2021 was $440,000 and none for the nine months ended March 31, 2020. There was no cash provided or used by the discontinued operations for financing activities for both the current and prior year periods.

10.Payroll Protection Program Loans

The Company has two Payroll Protection Program (“PPP”) loans outstanding which are comprised of $563,800 received in April 2020 and $433,800 received in March 2021 through its bank. The loans each bear interest at 1% per annum and mature in April 2022 and March 2026, respectively, and contain no collateral or guarantee requirements. The Company expects to apply and receive forgiveness for both loans.

At the 2020 Annual Meeting of Stockholders, the stockholders of the Company approved an amendment to the Certificate of Incorporation of the Company to increase the number of authorized shares of the Company’s Common stock by 3,000,000shares from 7,000,000 to 10,000,000 shares, which is reflected as of March 31, 2021.

In addition, the stockholders also approved an amendment to the Company’s 2012 Stock Option Plan (“Plan”) to increase the number of shares under the Plan by 943,000 shares, from 307,000 to 1,250,000 shares, which, together with 150,000 shares that were added to the Plan in 2020, the Company registered on a Form S-8 Registration Statement with the Securities and Exchange Commission on March 15, 2021. The Company’s Board of Directorsauthorized and approved the grant of Stock Options in June 2020 and July 2020 to three key officers, subject to availability of option shares. In February 2021, upon availability, the Company issued these stock options to the Company’s Chairman of the Board, its Chief Executive Officer and President, and the Chief Commercial Officer of the Company’s Bioprocessing Systems Operations, which resulted in total stock-based compensation of $1,292,000 and $1,429,400 for the three and nine months ended March 31, 2021, which also included expense for other optionees.

12. Subsequent Events

On April 29 2021, the Company received proceeds of approximately $7,580,500 from the sale of its securities to private investors upon the issuance of 1,595,880 shares of the Company’s Common Stock at an offering price of $4.75 per share which included warrants to purchase up to 797,940 shares of the Company’s Common Stock at $9.50 per share.

These warrantsare exercisable immediately and expire five years from date of issuance.

Using the proceeds received, the Company, through its newly organized wholly owned subsidiary Scientific Bioprocessing Holdings, Inc., purchased 100% of the capital stock in aquila biolabs, GmbH (“Aquila”), a German bioprocessing company, for approximately $7,880,000. This acquisition was completed so both Aquila and SBI can create synergies in product development and sales opportunities for all products in the United States, Europe and other parts of the world. Concurrent with the acquisition, the Company entered into employment agreements with the four managing directors of Aquila. The Company has not completed any other items required to be disclosed as more time is needed in order to complete all of the necessary calculations. In addition, certain disclosures of revenues and earnings of Aquila since the acquisition are impracticable as they are minimal to the Company as a whole.

Forward-Looking statements. Certain statements contained in this report are not based on historical facts, but are forward-looking statements that are based upon various assumptions about future conditions. Actual events in the future could differ materially from those described in the forward-looking information. Numerous unknown factors and future events could cause such differences, including but not limited to, product demand, market acceptance, success of marketing strategy, success of expansion efforts, impact of competition, adverse economic conditions, and other factors affecting the Company’s business that are beyond the Company’s control, which are discussed elsewhere in this report. Consequently, no forward-looking statement can be guaranteed. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Company’s financial statements and the related notes included elsewhere in this report.

The Company reflected ~~income~~a loss from continuing operations before income tax benefit of $1,830,200 and $2,205,200 for the three and nine months ended March 31, 2021 compared to a loss of $276,900 and $88,900 for the three and nine months ended March 31, 2020, primarily due to increased operating expenses incurred by the Company’s Bioprocessing Systems Operations, stock options expense amounting to $1,292,000 and $1,429,400 for the three and nine months ended March 31, 2021 compared to $14,600 and $50,000 for the three and nine months ended March 31 2020, and expenses related to mergers and acquisitions (“M&A”) activities. The results reflected the Company’s continued expansion of ~~$16,400~~its Bioprocessing Systems Operations with increased personnel and expenditures for product development, sales, and marketing activities, and M&A activity, partially offset by the profits generated by increased sales of the Benchtop Laboratory Equipment Operations.

Results of Operations.

The Three Months Ended ~~December~~March 31, ~~2017~~2021 Compared ~~with~~With The Three Months Ended ~~December~~March 31, ~~2016~~2020

Net revenues for the three months ended ~~December~~March 31, ~~2017 decreased $791,400 (29.5%~~2021 increased $372,400 (17.4%) to ~~$1,892,400~~$2,508,600 from ~~$2,683,800~~$2,136,200 for the three months ended ~~December~~March 31, ~~2016,~~2020, reflecting ~~a decrease~~an increase of ~~$1,038,600~~$565,000 in ~~net sales of catalyst research instruments due to decreased orders from Original Equipment Manufacturer OEM customers and lack of large orders, partially offset by increased~~ sales of benchtop laboratory equipment, ~~of $219,400 and bioprocessing~~partially offset by decreased earned royalties of ~~$27,800.~~$193,600 by the Bioprocessing Systems Operations. The Company’s benchtop laboratory equipment sales reflected ~~$359,900~~$466,200 and $430,400 of Torbal brand product gross sales for the three months ended ~~December~~March 31, 2017, compared to $303,500 in the three months ended December 31, 2016. As of December 31, 2017, the order backlog for catalyst research instruments was $752,500, all of which is expected to be shipped during fiscal year ending June 30, 2018, compared to $397,300 as of December 31, 2016.2021 and 2020, respectively.

The overall gross profit percentage for the three months ended ~~December~~March 31, ~~2017~~2021 was ~~40.5%~~54.3% compared to ~~29.6%~~51.5% for the three months ended ~~December~~March 31, ~~2016. The current year period gross margin~~2020, reflecting increased margins for the Benchtop Laboratory Equipment Operations ~~was higher~~ due to increased sales. The gross profit for the ~~effect of the allocation of fixed costs on higher sales. The catalyst research instruments~~Bioprocessing Systems Operations was ~~negatively~~positively impacted by the recording of an amount related to expected lower ~~sales.~~future contingent consideration payments resulting from expected lower future royalties.

General and administrative expenses for the three months ended ~~December~~March 31, ~~2017 amounted~~2021 increased by $875,900 (171.8%) to ~~$407,900~~$1,385,600 compared to ~~$409,200~~$509,700 for the three months ended ~~December~~March 31, ~~2016.~~2020, due to the expansion of the Scientific Bioprocessing Systems Operations, stock options expense, and expenses related to M&A activities.

Selling expenses for the three months ended ~~December~~March 31, ~~2017 decreased $9,600 (4.3%~~2021 increased $1,041,200 (301.9%) to ~~$214,600~~$1,386,100 from ~~$224,200~~$344,900 for the three months ended ~~December~~March 31, ~~2016,~~2020, due to ~~lower~~increased sales and marketing costs related to personnel (including stock options expense), websites, market research, and advertising expenses incurred by the Bioprocessing Systems Operations, and to a lesser extent increased online marketing for the ~~Catalyst Research Instruments Operations.~~Benchtop Laboratory Equipment Operations’ Torbal pill counter product line.

Research and development expenses increased by ~~$27,900 (26.6%~~$151,100 (50.6%) to ~~$132,900~~$450,000 for the three months ended ~~December~~March 31, ~~2017~~2021 compared to ~~$105,000~~$298,900 for the three months ended ~~December~~March 31, ~~2016,~~2020, primarily due to ~~increased~~the ramp up in product development activities by the Bioprocessing Systems Operations which included staffing, facilities, and materials and to new product development costs ~~incurred by~~related to the Benchtop Laboratory Equipment ~~Operations~~Operations.

In the three months ended March 31, 2020, the Company reflected a non-recurring charge of termination costs for the severance pay and related payroll costs, pertaining to the ~~Torbal Scales Division.~~early termination in February 2020 of the Company's Vice President of Corporate Strategy and Vice President of Sales for the Company's wholly-owned subsidiary, Altamira Instruments, Inc. which was sold at the end of the second quarter.

Total other income ~~decreased by $2,200 (26.5%) from $8,300~~(expense), net was $28,600 for the three months ended ~~December~~March 31, ~~2016~~2021 compared to ~~$6,100~~($41,900) for the three months ended ~~December~~March 31, ~~2017~~2020, primarily due to ~~lower~~increased interest and dividend income generated from investment securities, and holding losses on ~~its investment securities.~~investments in the prior year period.

The Company reflected an income tax ~~expense~~benefit related to continuing operations of ~~$97,400~~$378,200 for the three months ended ~~December~~March 31, ~~2017~~2021 compared to ~~income tax expense of $19,500~~$45,500 for the three months ended ~~December~~March 31, ~~2016,~~2020 due to the increased loss for the period.

The Company reflected income from discontinued operations of $16,400 for the three months ended March 31, 2021, compared to a $99,600 loss for the three months ended March 31, 2020, primarily due to ~~a revision~~revenue generated post-sale of substantially all the ~~estimate~~assets of Altamira Instruments, Inc.

The Company reflected no income tax expense or benefit for the ~~Company's expected annual income.~~
three months ended March 31, 2021 and an income tax benefit related to discontinued operations of $16,400 for the three months ended March 31, 2020 due to the loss during the prior year period.

The net income from discontinued operations was $16,400 for the three months ended March 31, 2021 compared to net loss of $83,200 for the three months ended March 31, 2020, primarily due to revenue generated post-sale of substantially all the assets of Altamira Instruments, Inc.

As a result of the foregoing, the Company recorded a net loss of ~~$81,000~~$1,435,600 for the three months ended ~~December~~March 31, ~~2017~~2021 compared to a net ~~income $45,300~~loss of $314,600 for the three months ended ~~December~~March 31, ~~2016.~~2020.

The ~~Six~~Nine Months Ended ~~December~~March 31, ~~2017~~2021 Compared ~~with~~With The ~~Six~~Nine Months Ended ~~December~~March 31, ~~2016~~2020

General and administrative expenses for the ~~six~~nine months ended ~~December~~March 31, ~~2017~~2021 increased ~~slightly by $14,700 (1.8%~~$983,600 (67.5%) to ~~$836,300 compared to $821,600~~$2,441,700 from $1,458,100 for the ~~six~~nine months ended ~~December~~March 31, ~~2016.~~2020, due to the expansion of the Scientific Bioprocessing Systems Operations, stock options expense, and expenses related to M&A activities.

Selling expenses for the ~~six~~nine months ended ~~December~~March 31, ~~2017 decreased $25,300 (5.7%~~2021 increased $1,778,600 (202.0%) to ~~$415,600~~$2,658,900 from ~~$440,900~~$880,300 for the ~~six~~nine months ended ~~December~~March 31, ~~2016,~~2020, due to ~~lower~~increased sales and marketing costs related to personnel (including stock options expense), websites, market research, and advertising expenses incurred by the Bioprocessing Systems Operations, and to a lesser extent increased online marketing for the ~~Catalyst Research Instruments Operations.~~

Research and development expenses increased by ~~$41,600 (18.9%~~$228,700 (28.8%) to ~~$262,000~~$1,024,000 for the ~~six~~nine months ended ~~December~~March 31, ~~2017~~2021 compared to ~~$220,400~~$795,300 for the ~~six~~nine months ended ~~December~~March 31, ~~2016,~~2020, primarily due to ~~increased~~the ramp up in product development activities by the Bioprocessing Systems Operations which included staffing, facilities, and materials and to new product development costs ~~incurred by~~related to the Benchtop Laboratory Equipment ~~Operations~~Operations.

In the nine months ended March 31, 2020, the Company reflected a non-recurring charge of termination costs for the severance pay and related payroll costs, pertaining to the ~~Torbal Scales Division.~~early termination in February 2020 of the Company's Vice President of Corporate Strategy and Vice President of Sales for the Company's wholly-owned subsidiary, Altamira Instruments, Inc. which was sold at the end of the second quarter.

Total other income ~~decreased by $7,300 (53.3%) from $13,700~~(expense), net was $93,700 for the ~~six~~nine months ended ~~December~~March 31, ~~2016~~2021 compared to ~~$6,400~~($30,100) for the ~~six~~nine months ended ~~December~~March 31, ~~2017~~2020, primarily due to ~~lower~~increased interest ~~on its~~and dividend income generated from investment securities, and ~~miscellaneous income items.~~holding losses on investments in the prior year period.

The Company reflected an income tax ~~expense~~benefit related to continuing operations of ~~$23,500~~$472,300 for the ~~six~~nine months ended ~~December~~March 31, ~~2017~~2021 compared to $15,000 for the nine months ended March 31, 2020 due to the increased loss for the current year period.

The Company reflected a loss from discontinued operations of $758,400 for the nine months ended March 31, 2021, compared to $360,300 for the nine months ended March 31, 2020, due to the loss on disposal in the current year period.

The Company reflected an income tax benefit related to discontinued operations of ~~$1,300~~$179,900 for the ~~six~~nine months ended ~~December~~March 31, ~~2016,~~2021 compared to $67,000 for the nine months ended March 31, 2020 due to the increased loss during the current year period.

The net loss from discontinued operations was $578,500 for the nine months ended March 31, 2021 compared to $293,300 for the nine months ended March 31, 2020, primarily due to the ~~statutory federal tax rate change resulting from~~loss on disposal during the ~~recently enacted 2017 Tax Act, including a write off of deferred tax assets of $15,500.~~
current year period.

As a result of the foregoing, the Company recorded a net loss of ~~$313,600~~$2,311,400 for the ~~six~~nine months ended ~~December~~March 31, ~~2017~~2021 compared to ~~$3,400~~a net loss of $367,200 for the ~~six~~nine months ended ~~December~~March 31, ~~2016.~~2020.

Liquidity and Capital Resources. Cash and cash equivalents decreased by ~~$324,400~~$6,932,200 to ~~$700,700~~$627,500 as of ~~December~~March 31, ~~2017~~2021 from ~~$1,025,100~~$7,559,700 as of June 30, ~~2017~~2020, primarily due to ~~decreased~~converting cash ~~generated by~~on-hand to short term liquid investment securities and the ~~Catalyst Research Instrument Operations and increased inventories.~~loss for the period.

Net cash used in operating activities was ~~$133,700~~$2,592,500 for the ~~six~~nine months ended ~~December~~March 31, ~~2017~~2021 compared to ~~$450,300~~net cash used of $803,800 during the ~~six~~nine months ended ~~December~~March 31, ~~2016. The current period reflected higher accounts payable and customer advances, partially offset by~~2020, primarily due to the increased ~~prepaid expenses and higher inventories.~~loss for the period. Net cash used in investing activities was ~~$84,600~~$4,763,100 for the ~~six~~nine months ended ~~December~~March 31, ~~2017~~2021 compared to ~~$27,000~~$66,300 used during the ~~six~~nine months ended ~~December~~March 31, ~~2016~~2020, principally due to net purchases of investments, and to a lesser extent new capital equipment ~~purchased~~purchases by the Bioprocessing Systems Operations during the current ~~year~~ period, partially offset by the ~~Benchtop Laboratory Equipment Operations. The Company used $106,100 in~~cash received from the sale of the subsidiary. Net cash provided by financing activities inwas $423,400 for the ~~six~~nine months ended ~~December~~March 31, ~~2017~~2021, due to a Payroll Protection Program loan received by the Federal Government, compared to ~~cash~~$7,000 provided ~~of $129,400 in~~during the ~~six~~nine months ended ~~December~~March 31, ~~2016 mainly due~~2020 from cash proceeds related to ~~decreased proceeds under~~ the ~~line~~exercises of ~~credit in the current year.~~stock options.

The Company's working capital decreased by ~~$191,500~~$1,222,600 to ~~$3,782,400~~$9,325,900 as of ~~December~~March 31, ~~2017~~2021 compared to ~~$3,973,900,~~$10,548,500, as of June 30, ~~2017~~2020 mainly due to ~~increased capital expenditures and a net~~the loss ~~incurred~~ during the ~~current~~ period.

The Company has a Demand Line of Credit through ~~June 2018~~December 2021 with First National Bank of Pennsylvania which provides for borrowings of up to $300,000 for regular working capital needs, bearing interest at prime, ~~currently 4.5%.~~3.25% currently. Advances on the line, are secured by a pledge of the Company’s assets including inventory, accounts, chattel paper, equipment and general intangibles of the Company. As of ~~December~~March 31, ~~2017 $40,000 which was borrowed by our subsidiary, Altamira Instruments, was~~2021, no borrowings were outstanding under such line. In addition, the Company utilized $245,400 of its borrowing availability under the line as collateral for a warranty standby letter of credit required during a two year warranty period as a condition of sale for a large order of catalyst research instruments shipped in a prior fiscal year and installed in the first quarter of fiscal 2018, leaving an available borrowing balance of $14,600 under the line of credit.

Management believes that the Company will be able to meet its cash flow needs during the 12 months ending ~~June 30, 2018~~March 31, 2022 from its available financial resources including, its ~~line of credit, its~~ cash and investment securities, operations and ~~operations.~~the line of credit.

~~Item~~item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures. As of the end of the period covered by this report, based on an evaluation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), the Chief Executive and Chief Financial Officer of the Company has concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in its Exchange Act reports is recorded, processed, summarized and reported within the applicable time periods specified by the SEC's rules and forms. The Company also concluded that information required to be disclosed in such reports is accumulated and communicated to the Company's management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting. There was no change in the Company's internal controls over financial reporting that occurred during the most recently completed fiscal quarter that materially affected or is reasonably likely to materially affect the Company's internal controls over financial reporting.

PART II – OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K

Exhibit Number		Description
~~31.1~~
31.		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
~~32.1~~ 32.		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Reports on Form 8-K: ~~None~~

Current Report filed on Form 8-K dated July 22, 2020 reporting under Items 1.01 and 5.2.

Current Report filed on Form 8-K dated August 13, 2020 reporting under Item 5.03.

Current Report filed on Form 8-K dated December 1, 2020 reporting under Items 1.01 and 2.01.

14 18

S~~IGNATURE~~SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: ~~February 14, 2018~~May 17, 2021	SCIENTIFIC INDUSTRIES, INC. (Registrant) /s/ Helena R. Santos
	Helena R. Santos President, Chief Executive Officer, Treasurer Chief Financial and Principal Accounting Officer

15 19

	December 31, 2017	June 30, 2017	March 31, 2021	June 30, 2020
Current assets:	(Unaudited)		(Unaudited)
Cash and cash equivalents	$700,700	$1,025,100	$627,500	$7,559,700
Investment securities	314,700	295,500	5,325,700	331,800
Trade accounts receivable, less allowance for doubtful accounts of $11,600 at December 31, 2017 and June 30, 2017	1,475,300	1,424,400
Trade accounts receivable, less allowance for doubtful accounts of $11,600 at March 31, 2021 and June 30, 2020			1,822,500	1,064,000
Inventories	2,392,600	1,961,200	2,885,200	2,541,000
Income tax receivable			336,300	334,800
Prepaid expenses and other current assets	146,600	80,300	62,600	112,400
Assets of discontinued operations			124,600	793,000
Total current assets	5,029,900	4,786,500	11,184,400	12,736,700

Property and equipment, net	235,600	199,300	383,700	278,300

Intangible assets, net	458,300	579,000	121,500	128,700

Goodwill	�� 705,300	705,300	257,300

Other assets	52,500		48,400	56,000

Deferred taxes	488,600	505,100	1,189,400	537,100

Operating lease right-of-use assets			715,600	803,300

Total assets	$6,970,200	$6,827,700	$13,900,300	$14,797,400

Current liabilities:
Accounts payable	$379,400	$139,200	$477,200	$334,600
Accrued expenses, current portion	466,500	491,000
Bank line of credit	40,000	-
Customer advances	321,800	-
Accrued expenses			456,400	679,000
Contract liabilities			-	20,000
Contingent consideration, current portion	33,000	175,700	195,800	111,000
Notes payable, current portion	6,800	6,700

Bank overdraft			50,600	43,100
Liabilities of discontinued operations			64,400	240,900
Operating lease liabilities, current portion			50,300	195,800
Payroll Protection Program loan, current portion			563,800
Total current liabilities	1,247,500	812,600	1,858,500	2,188,200

Accrued expenses, less current portion	60,000
Notes payable, less current portion	2,300	5,800
Payroll Protection Program loan, less current portion			433,800	-
Contingent consideration payable, less current portion	121,300		30,300	247,000
Operating lease liabilities, less current portion			735,300	640,800

Total liabilities	1,431,100	999,700	3,057,900	3,076,000
Shareholders’ equity:
Common stock, $.05 par value; authorized 7,000,000 shares; issued 1,513,914 shares outstanding at December 31, 2017 and June 30, 2017	75,700
Shareholders’ equity: Common stock, $.05 par value; 10,000,000 and 7,000,000 shares authorized; 2,882,065 and 2,881,065 shares issued; 2,862,263 and 2,861,263 shares outstanding at March 31, 2021 and June 30, 2020
			144,200	144,100
Additional paid-in capital	2,536,400	2,515,900	10,040,600	8,608,300
Accumulated other comprehensive income (loss)	700	(3,500)
Retained earnings	2,978,700	3,292,300	710,000	3,021,400
	5,591,500	5,880,400	10,894,800	11,773,800
Less common stock held in treasury at cost, 19,802 shares	52,400		52,400

Total shareholders’ equity	5,539,100	5,828,000	10,842,400	11,721,400

Total liabilities and shareholders’ equity	$6,970,200	$6,827,700	$13,900,300	$14,797,400

	December 31, 2017	June 30, 2017
			March 31, 2021	June 30, 2020
Raw materials	$1,502,000	$1,373,800	$2,191,200	$1,726,400
Work-in-process	476,300	166,500	74,100	35,700
Finished goods	414,300	420,900	619,900	778,900

	$2,392,600	$1,961,200	$2,885,200	$2,541,000

	For the Three Month Period Ended December 31,	For the Three Month Period Ended December 31,	For the Six Month Period Ended December 31,	For the Six Month Period Ended December 31,
	2017	2016	2017	2016

Revenues	$1,892,400	$2,683,800	$3,173,300	$4,242,900

Cost of revenues	1,126,700	1,888,900	1,955,900	2,778,400

Gross profit	765,700	794,900	1,217,400	1,464,500

Operating expenses:
General and administrative	407,900	409,200	836,300	821,600
Selling	214,600	224,200	415,600	440,900
Research and development	132,900	105,000	262,000	220,400

Total operating expenses	755,400	738,400	1,513,900	1,482,900

Income (loss) from operations	10,300	56,500	(296,500)	(18,400)

Other income (expense):
Interest income	5,200	8,800	5,600	9,100
Other income, net	1,400	400	1,400	5,700
Interest expense	(500)	(900)	(600)	(1,100)

Total other income, net	6,100	8,300	6,400	13,700

Income (loss) before income tax expense (benefit)	16,400	64,800	(290,100)	(4,700)

Income tax expense (benefit):
Current	71,800	20,900	8,000	(15,400)
Deferred	25,600	(1,400)	15,500	14,100

Total income tax expense (benefit)	97,400	19,500	23,500	(1,300)

Net income (loss)	$(81,000)	$45,300	$(313,600)	$(3,400)

Basic earnings (loss) per common share	$(.05)	$.03	$(.21)	$.00

Diluted earnings (loss) per common share	$.(05)	$.03	$(.21)	$.00

Cash dividends declared per common share	$.00	$.03	$.00	$.03

	Benchtop Laboratory Equipment	Catalyst Research Instruments	Bioprocessing Systems	Corporate And Other	Consolidated
Three Months Ended December 31, 2017:

Revenues	$1,686,200	$153,500	$52,700	$-	$1,892,400

Foreign Sales	815,300	2,600	-	-	817,900

Income (Loss) From Operations	122,000	(103,400)	(8,300)	-	10,300

Assets	4,085,800	1,613,200	467,900	803,300	6,970,200

Long-Lived Asset Expenditures	33,000	1,900	2,500	-	37,400

Depreciation and Amortization	67,000	700	9,300	-	77,000

	Benchtop Laboratory Equipment	Catalyst Research Instruments	Bioprocessing Systems	Corporate And Other	Consolidated
Three Months Ended December 31, 2016:

Revenues	$1,466,800	$1,192,100	$24,900	$-	$2,683,800

Foreign Sales	751,800	10,300	-	-	762,100

Income (Loss) From Operations	62,600	26,600	(32,700)	-	56,500

Assets	4,131,400	1,982,800	434,700	695,900	7,244,800

Long-Lived Asset Expenditures	5,200	-	5,800	-	11,000

Depreciation and Amortization	76,700	4,500	12,600	-	93,800

		Fair Value Measurements Using Inputs Considered as
	Fair Value at June 30, 2017	Level 1	Level 2	Level 3

Assets:

Cash and cash equivalents	$1,025,100	$1,025,100	$-	$-
Available for sale securities	295,500	295,500	-	-

Total	$1,320,600	$1,320,600	$-	$-

Liabilities:

Contingent consideration	$297,000	$-	$-	$297,000

	2017	2016
Beginning balance	$297,000	$346,300
Payments	(142,700)	(117,400)

Ending balance	$154,300	$228,900

	For the Three Month Period Ended December 31, 2017	For the Three Month Period Ended December 31, 2016	For the Six Month Period Ended December 31, 2017	For the Six Month Period Ended December 31, 2016

Net income (loss)	$(81,000)	$45,300	$(313,600)	$(3,400)

Weighted average common shares outstanding	1,494,112	1,489,112	1,494,112	1,489,112

Basic and diluted earnings (loss) per common share	$(.05)	$.03	$(.21)	$(.00)